Participants lost an average of 14.9% of their body weight
Key risk factors for pancreatitis that warrant heightened vigilance include: Hypertriglyceridemia : Triglyceride levels above 500 mg/dL increase pancreatitis risk, with markedly elevated risk when levels exceed 1,000 mg/dL
Landmark trials, including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW, have demonstrated their efficacy in preserving kidney function and reducing adverse outcomes
Your prescriber should establish: Baseline measurements : Weight, blood pressure, mood assessment, and relevant blood tests Follow-up schedule : Regular appointments to monitor progress, side effects, and treatment response Target outcomes : Specific, measurable goals for both weight management and smoking cessation Duration of treatment : Wegovy is typically prescribed for up to 2 years in the NHS